Dr Langevin

Clinical Trials for Movement Disorders

Clinical trials are research studies that explore newer treatment strategies for patients who are no longer responding to current treatments or who are eligible for a new therapy approach.

Data collected throughout the course of a trial helps develop a deeper understanding of the disease continuum and depending upon your condition, we may recommend participation in a clinical trial.

Clinical trials differ from a doctor’s office visit where the goal is to diagnose and treat the disease with established therapies. Rather clinical trials use of new therapies, current treatments used in an innovative way, or new surgical procedures. An Institutional Review Board (IRB) approval is always obtained prior to activating a study weighing the risks and benefits of a study. The IRB ensures that the clinical trial is conducted in accordance with all federal, institutional, and ethical guidelines.

Ask one of our specialists if you are eligible for a clinical trial protocol.

Clinical Trials

Enrollment Open

Synuclein-One (NCT04700722)

We are seeking subjects to participate in an important clinical study.

  • Men and women 40-99 years old
  • Clinical diagnosis of Parkinson’s disease, multiple system atrophy, dementia with Lewy bodies or pure autonomic failure
  • You won’t be able to participate if you use blood thinners (but Plavix or aspirin alone is allowed)

It just takes one in-person visit and you’ll earn $50 for helping out! If you would like to participate, speak with your physician.

213-712-7731 |  marisol.savage@providence.org

PRAX-944 for Essential Tremor (NCT05021991)

PNI is seeking adult participants with essential tremor for a phase 2, randomized, double-blind, placebo-controlled trial of PRAX-944 to evaluate its safety and efficacy.

Essential Tremor (ET) is one of the most common neurological disorders with a prevalence of nearly 2% in the US. Researchers at the Pacific Movement Disorders Center at Pacific Neuroscience Institute (PNI) are participating in a clinical trial to find novel treatments for essential tremor.

If you are interested and want to learn more, please contact the research team:

213-712-7731 | neuro.trials@pacificneuro.org

Enrollment Complete / Trial Closed

  1. To examine the current disease progression of Parkinson’s disease psychosis (PDP), the clinical, economic, and humanistic impact of anti-psychotic therapy in the management of the condition in real-world settings, and the burden of the condition on patients and their caregivers.
  2. This is an open-label study of the Cala TWO device with home usage for 3 months to assess for duration of effect over the course of the trial. The device is a non-invasive peripheral neurostimulator for essential tremor and the study is open to patients with mild, moderate, and severe essential tremor.